Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moss-aGal in Fabry Disease
NCT02995993Phase 1Completed
- Sponsor
- Greenovation Biotech GmbH
- Start
- Nov 2016
- Primary completion
- Oct 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of moss-agal in Fabry disease (FD), sponsored by Greenovation Biotech GmbH. Primary endpoints: Area Under the Curve from time zero to infinity at 24 hours and Number of patients with drug-related adverse events at 28 days. Started Nov 2016; status: completed.
02
Drugs
moss-agal
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT02995993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995993.